aibio
Listings ·
Nasdaq files Form 25 to delist Avenue Therapeutics common stock
The Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.
ATXI Avenue Therapeutics, Inc.
Avenue Therapeutics (ATXI) news ATXI delisting news
Latest Avenue Therapeutics news
- Mergers
Avenue Therapeutics ends AJ201 license and transfers program back to AnnJi
AnnJi will pay Avenue $2.0 million over 90 days, plus possible milestones and a 1.75% royalty.
- Listings
Nasdaq panel delists Avenue Therapeutics; stock moves to OTC on March 19, 2025
The company failed to meet Nasdaq's $2,500,000 stockholders' equity rule by the panel's deadline. Trading moves to the OTC Markets under the ATXI symbol.
What Avenue Therapeutics does
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases. It is a majority-controlled subsidiary of Fortress Biotech, Inc. Its lead program, ATX-04, is a selective beta-2 adrenergic agonist for which the company obtained an exclusive worldwide license from Duke University in February 2026, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy. A 52-week Phase I/II clinical study at Duke in patients with Pompe disease reported improvements in six-minute walk distance and respiratory muscle strength. The company is preparing a pre-IND meeting with the FDA to align on a pivotal study design. Its other product candidate, intravenous tramadol, is a schedule IV opioid for post-operative acute pain that the company licenses from Revogenex for the United States. The company submitted a New Drug Application for IV tramadol in December 2019. In November 2025 it agreed that Axsome Therapeutics would acquire Baergic Bio, which held the BAER-101 asset, and in April 2025 it ended its AJ201 license with AnnJi Pharmaceutical.
| Product or program | What it is | Stage |
|---|---|---|
| ATX-04 | Selective beta-2 adrenergic agonist for Pompe disease as an adjunct to ERT | Phase I/II study conducted at Duke; pre-IND meeting being prepared |
| IV tramadol | Schedule IV opioid for post-operative acute pain | NDA submitted in December 2019 |
Avenue Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.4 million | $0 |
| Research and development | $1.0 million | $6.6 million |
| Net income (loss) | -$2.9 million | -$11.7 million |
| Cash from operations | -$1.8 million | -$9.0 million |
| Cash and equivalents | $2.9 million | $2.6 million |
Questions about Avenue Therapeutics
Was Avenue Therapeutics delisted?
Our latest story on this, dated Jul 18, 2025: "Nasdaq files Form 25 to delist Avenue Therapeutics common stock". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Avenue Therapeutics?
Avenue Therapeutics, Inc. trades under the ticker ATXI on OTC.
Where is Avenue Therapeutics listed?
Avenue Therapeutics, Inc. is listed on OTC.
What is the SEC CIK of Avenue Therapeutics?
The SEC Central Index Key (CIK) for Avenue Therapeutics, Inc. is 1644963. Its filings are on SEC EDGAR.
How many shares does Avenue Therapeutics have outstanding?
3,294,967 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07.
Which country or territory is Avenue Therapeutics listed under?
Our directory records Avenue Therapeutics, Inc. under United States.
What does Avenue Therapeutics do?
Our directory classifies Avenue Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Avenue Therapeutics?
The ISIN recorded for Avenue Therapeutics, Inc. is US05360L4032.
Does aibio.space cover Avenue Therapeutics?
aibio.space lists Avenue Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Avenue Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Avenue Therapeutics develop?
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases. It is a majority-controlled subsidiary of Fortress Biotech, Inc. Its lead program, ATX-04, is a selective beta-2 adrenergic agonist for which the company obtained an exclusive worldwide license from Duke University in February 2026, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy.
What is ATX-04 from Avenue Therapeutics?
ATX-04: Selective beta-2 adrenergic agonist for Pompe disease as an adjunct to ERT Stage: Phase I/II study conducted at Duke; pre-IND meeting being prepared.
What is IV tramadol from Avenue Therapeutics?
IV tramadol: Schedule IV opioid for post-operative acute pain Stage: NDA submitted in December 2019.
What was Avenue Therapeutics's revenue last year?
$1.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Avenue Therapeutics profitable?
Avenue Therapeutics, Inc. reported a net loss of $2.9 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC.
Investor discussion: Avenue Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Stock chart
SEC filings and registration
- SEC name
- Avenue Therapeutics, Inc.
- CIK
- 1644963
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ATXI (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL, 33154
- Phone
- 781-652-4500
- Shares outstanding
- 3,294,967 as of 2026-08-04 (10-Q filed 2026-08-07)
Recent filings
Listing details
- Company
- Avenue Therapeutics, Inc.
- Ticker
- ATXI
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US05360L4032
- Last quote in directory
- 2026-10-20
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction